background recent studi demons mesenchym stem cell msc model immune response reduce lung injury anim model current clinic effect act respiratory distress syndrome ard exist object studi first examine possible adverse event system administer allowed adiposederiv patient second determine potent efficacy method twelve adult meet berlin deficit profit ratio random receive placebo fashion receive one intranet dose cells body weight salon side monitor treatment biomass include il surface protein spd examine inflamed result infos toxic serious relay signifies differ overall number two group length host stay ventilatorfre day cure day similar chang group serum level significantly lower p show trend toward compare status concur appear safe feasible howe effect dose use weak optic strategy probably require reach goal reduce alveolar epithet trial register trialsgov not 